Clinical trial

A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

NCT02913443

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention RO7051790 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-12-20

PhasePHASE1

Conditions

Small Cell Lung Cancerverified · MONDO: small cell lung carcinoma

Interventions

RO7051790DRUG

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

MadridSpain2 TorontoOntario, Canada1 BarcelonaSpain1 BirminghamAlabama, United States1 OttawaOntario, Canada1 VillejuifFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02913443 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.